AstraZeneca Crestor Copromotion Decision Coming: Nexium Has 6% Share
Executive Summary
AstraZeneca expects to make a decision on whether to use a copromotion partner for the HMG-CoA reductase inhibitor Crestor (rosuvastatin) within "the next six to eight weeks," CFO Jonathan Symonds told the Goldman Sachs healthcare conference June 12 in Dana Point, Calif.
You may also be interested in...
AstraZeneca To "Go It Alone" For Crestor, Cites Large Market Opportunity
AstraZeneca will pursue a solo marketing strategy for Crestor (rosuvastatin) based on the larger market outlined in recently issued cholesterol treatment guidelines.
AstraZeneca To "Go It Alone" For Crestor, Cites Large Market Opportunity
AstraZeneca will pursue a solo marketing strategy for Crestor (rosuvastatin) based on the larger market outlined in recently issued cholesterol treatment guidelines.
Crestor on track for action in mid-2002
AstraZeneca submits NDA for Crestor (rosuvastatin) to FDA June 26. The company expects a standard review for the cholesterol-lowering agent. A decision on whether to sign up a co-promotion partner is expected shortly (1"The Pink Sheet" June 18, p. 10)